Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a leading regenerative medicine company with a strong portfolio of products focused on advanced wound care and surgical/sports medicine markets. Multiple regulatory pathways, including PMA, 510k, and 361 approvals, demonstrate a differentiated approval status and potential for market growth. With a robust clinical pipeline, strong executive leadership, and solid financials, Organogenesis is well-positioned for future success and potential acquisition as the industry consolidates.

Bears say

Organogenesis Holdings is facing major headwinds in the advanced wound care market due to recent reimbursement changes and market consolidation. These factors are causing uncertainty and confusion among providers, leading to a significant decline in revenue and profitability. While the company has a strong portfolio of products and potential opportunities for growth, it will take time for the market to stabilize and for the company to regain positive momentum. Additionally, the potential approval of their newest product, ReNu, presents a promising opportunity but remains uncertain and will likely not have a significant impact on the company's near-term financials. As a result, there is a high level of risk and limited visibility for Organogenesis Holdings, leading to a negative outlook for their stock.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.